What is Unicycive Therapeutics, Inc.'s (UNCY) StockRank?

MoatMap's StockRank for Unicycive Therapeutics, Inc. (UNCY) is 39/100, with a Hold signal. This is a composite score combining Quality (31), Value (25), and Momentum (73) factor ranks across MoatMap's 20,000+ stock universe.

Does Unicycive Therapeutics, Inc. have an economic moat?

Unicycive Therapeutics, Inc. (UNCY) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Unicycive Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Unicycive Therapeutics, Inc. (UNCY) is Hold, based on a StockRank of 39/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Unicycive Therapeutics, Inc. in?

Unicycive Therapeutics, Inc. (UNCY) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

UNCY

HOLDREMOVE

Unicycive Therapeutics, Inc. · Healthcare · United States · $210M · Avg Vol: $7M/d

StockRank

P/E (TTM)

—

ROE

-163.1%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

A micro-cap biopharmaceutical company with high volatility and no commercialized product portfolio. It fails our quality and scale requirements.

COMPANY DESCRIPTION

Unicycive Therapeutics, Inc. is a biotechnology company focused on developing novel treatments for patients with kidney disease and related conditions. Its competitive moat is derived from a pipeline of proprietary drug candidates, including a late-stage asset for hyperphosphatemia in chronic kidney disease patients on dialysis, addressing significant unmet medical needs. Unicycive is positioned as an emerging biopharmaceutical firm dedicated to nephrology innovations.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	1.0M	0.7M	0	0	-29.0%
EPS	-0.67	-1.62	-2.35	-1.67	—
Shares	27.4M	27.4M	27.4M	22.1M	-19.3%
Debt	0.2M	0.8M	0.8M	0.2M	-0.3%
Equity	-0.5M	-3.8M	7.4M	30.2M	306.4%
Op CF	-15.7M	-18.3M	-28.6M	-31.3M	—
Inv CF	-2,000	-12,000	-72,000	-12.1M	—
Fin CF	-0.5M	27.5M	45.1M	46.5M	—

PRICE (1Y)-3.4%

SMA 50SMA 200

$7.89

RSI (14)

58.1

52W High

$8.74

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

-87.7%6.4

ROE

-163.1%4.5

GP/Assets

—N/A

Op. Margin

0.0%40.3

FCF/Assets

-14.1%23.3

Piotroski

438.9

Int. Cover

-50.0x6.0

D/E Ratio

0.02x82.3

Current Ratio

2.40x44.9

Value

P/E (TTM)

—N/A

EV/EBITDA

-4.3x25.0

P/FCF

—N/A

P/B

5.3x24.8

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

90%70.9

RS 6M

34%80.9

SMA 50/200

1.21x89.8

EPS Rev 4W

-8.0%6.8

EPS Rev 12W

—N/A

EPS Improve

+368%93.9

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$210M

P/E (Forward)

1.3x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of UNCY are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
UNCY	Unicycive Therapeutics, Inc.(you)	$210M	39	HOLD
NKTX	Nkarta, Inc.	$205M	42	HOLD
EQ	Equillium, Inc.	$185M	41	HOLD
KPTI	Karyopharm Therapeutics Inc.	$202M	34	SELL
ANTX	AN2 Therapeutics, Inc.	$191M	33	SELL
DTIL	Precision BioSciences, Inc.	$179M	43	HOLD
SABS	SAB Biotherapeutics, Inc.	$310M	38	HOLD
IMUX	Immunic, Inc.	$199M	48	HOLD
CNTN	Canton Strategic Holdings, Inc.	$235M	30	SELL
PALI	Palisade Bio, Inc.	$335M	37	HOLD

Peer medians: ROE -23.1% · P/E 25.2x · Gross margin 44.3%

Unicycive Therapeutics, Inc. (UNCY) — Stock Score Summary

Unicycive Therapeutics, Inc. (UNCY) has a MoatMap StockRank of 39/100 based on Quality (31/100), Value (25/100), and Momentum (73/100) factor scores. The current signal is HOLD. A micro-cap biopharmaceutical company with high volatility and no commercialized product portfolio. It fails our quality and scale requirements.

Key Financial Metrics

Price	$7.89
Market Cap	$210M
P/E (Forward)	1.31
Price/Book	5.30
Return on Equity	-163.1%
Return on Invested Capital	-87.7%
Debt/Equity	2.16
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-7M

Unicycive Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Unicycive Therapeutics, Inc.’s (UNCY) StockRank?: MoatMap’s StockRank for Unicycive Therapeutics, Inc. (UNCY) is 39/100, with a Hold signal. It is a composite of Quality (31), Value (25), and Momentum (73) factor ranks across MoatMap’s 20,000+ stock universe.
Does Unicycive Therapeutics, Inc. have an economic moat?: Unicycive Therapeutics, Inc. (UNCY) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Unicycive Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Unicycive Therapeutics, Inc. (UNCY) is Hold, based on a StockRank of 39/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Unicycive Therapeutics, Inc. in?: Unicycive Therapeutics, Inc. (UNCY) operates in the Healthcare sector, specifically the Biotechnology industry (United States).